Literature DB >> 12429580

Inhibition of rat platelet aggregation by the diazeniumdiolate nitric oxide donor MAHMA NONOate.

Kerry L Homer1, Janet C Wanstall.   

Abstract

1. Inhibition of rat platelet aggregation by the nitric oxide (NO) donor MAHMA NONOate (Z-1-N-methyl-N-[6-(N-methylammoniohexyl)amino]diazen-1-ium-1,2-diolate) was investigated. The aims were to compare its anti-aggregatory effect with vasorelaxation, to determine the effects of the soluble guanylate cyclase inhibitor, ODQ (1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one), and to investigate the possible role of activation of sarco-endoplasmic reticulum calcium-ATPase (SERCA), independent of soluble guanylate cyclase, using thapsigargin. 2 MAHMA NONOate concentration-dependently inhibited sub-maximal aggregation responses to collagen (2-10 micro g ml(-1)) and adenosine diphosphate (ADP; 2 micro M) in platelet rich plasma. It was (i). more effective at inhibiting aggregation induced by collagen than by ADP, and (ii). less potent at inhibiting platelet aggregation than relaxing rat pulmonary artery. 3. ODQ (10 micro M) caused only a small shift (approximately half a log unit) in the concentration-response curve to MAHMA NONOate irrespective of the aggregating agent. 4. The NO-independent activator of soluble guanylate cyclase, YC-1 (3-(5'-hydroxymethyl-2'-furyl)-1-benzyl indazole; 1-100 micro M), did not inhibit aggregation. The cGMP analogue, 8-pCPT-cGMP (8-(4-chlorophenylthio)guanosine 3'5' cyclic monophosphate; 0.1-1 mM), caused minimal inhibition. 5. On collagen-aggregated platelets responses to MAHMA NONOate (ODQ 10 micro M present) were abolished by thapsigargin (200 nM). On ADP-aggregated platelets thapsigargin caused partial inhibition. 6. Results with S-nitrosoglutathione (GSNO) resembled those with MAHMA NONOate. Glyceryl trinitrate and sodium nitroprusside were poor inhibitors of aggregation. 7. Thus inhibition of rat platelet aggregation by MAHMA NONOate (like GSNO) is largely ODQ-resistant and, by implication, independent of soluble guanylate cyclase. A likely mechanism of inhibition is activation of SERCA.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12429580      PMCID: PMC1573589          DOI: 10.1038/sj.bjp.0704971

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  48 in total

1.  Inhibition of human platelet aggregation by a novel S-nitrosothiol is abolished by haemoglobin and red blood cells in vitro: implications for anti-thrombotic therapy.

Authors:  I L Megson; N Sogo; F A Mazzei; A R Butler; J C Walton; D J Webb
Journal:  Br J Pharmacol       Date:  2000-12       Impact factor: 8.739

2.  Complexes of .NO with nucleophiles as agents for the controlled biological release of nitric oxide. Vasorelaxant effects.

Authors:  C M Maragos; D Morley; D A Wink; T M Dunams; J E Saavedra; A Hoffman; A A Bove; L Isaac; J A Hrabie; L K Keefer
Journal:  J Med Chem       Date:  1991-11       Impact factor: 7.446

3.  A redox-based mechanism for the contractile and relaxing effects of NO in the guinea-pig gall bladder.

Authors:  S Alcón; S Morales; P J Camello; J M Hemming; L Jennings; G M Mawe; M J Pozo
Journal:  J Physiol       Date:  2001-05-01       Impact factor: 5.182

4.  NO-induced relaxation of labouring and non-labouring human myometrium is not mediated by cyclic GMP.

Authors:  I L Buxton; R A Kaiser; N A Malmquist; S Tichenor
Journal:  Br J Pharmacol       Date:  2001-09       Impact factor: 8.739

5.  The roles of P(2X1)and P(2T AC)receptors in ADP-evoked calcium signalling in human platelets.

Authors:  S O Sage; E H Yamoah; J W Heemskerk
Journal:  Cell Calcium       Date:  2000-08       Impact factor: 6.817

Review 6.  Diazeniumdiolates: pro- and antioxidant applications of the "NONOates".

Authors:  A L Fitzhugh; L K Keefer
Journal:  Free Radic Biol Med       Date:  2000-05-15       Impact factor: 7.376

7.  S-nitrosothiols cause prolonged, nitric oxide-mediated relaxation in human saphenous vein and internal mammary artery: therapeutic potential in bypass surgery.

Authors:  N Sogo; C Campanella; D J Webb; I L Megson
Journal:  Br J Pharmacol       Date:  2000-11       Impact factor: 8.739

8.  Cyclic GMP-independent relaxation of rat pulmonary artery by spermine NONOate, a diazeniumdiolate nitric oxide donor.

Authors:  K L Homer; J C Wanstall
Journal:  Br J Pharmacol       Date:  2000-10       Impact factor: 8.739

9.  Metabolic activation of sodium nitroprusside to nitric oxide in vascular smooth muscle.

Authors:  E A Kowaluk; P Seth; H L Fung
Journal:  J Pharmacol Exp Ther       Date:  1992-09       Impact factor: 4.030

10.  Role of cGMP and cGMP-dependent protein kinase in nitrovasodilator inhibition of agonist-evoked calcium elevation in human platelets.

Authors:  J Geiger; C Nolte; E Butt; S O Sage; U Walter
Journal:  Proc Natl Acad Sci U S A       Date:  1992-02-01       Impact factor: 11.205

View more
  7 in total

1.  The anti-aggregating effect of BAY 41-2272, a stimulator of soluble guanylyl cyclase, requires the presence of nitric oxide.

Authors:  Séverine Roger; Cécile Badier-Commander; Jérôme Paysant; Alex Cordi; Tony J Verbeuren; Michel Félétou
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

2.  A potential role for extracellular nitric oxide generation in cGMP-independent inhibition of human platelet aggregation: biochemical and pharmacological considerations.

Authors:  Michael S Crane; Adriano G Rossi; Ian L Megson
Journal:  Br J Pharmacol       Date:  2005-03       Impact factor: 8.739

3.  Mechanism of action of novel NO-releasing furoxan derivatives of aspirin in human platelets.

Authors:  Catriona M Turnbull; Clara Cena; Roberta Fruttero; Alberto Gasco; Adriano G Rossi; Ian L Megson
Journal:  Br J Pharmacol       Date:  2006-05-15       Impact factor: 8.739

4.  In Vivo Characterization of a Red Light-Activated Vasodilation: A Photobiomodulation Study.

Authors:  Agnes Keszler; Brian Lindemer; Grant Broeckel; Dorothee Weihrauch; Yan Gao; Nicole L Lohr
Journal:  Front Physiol       Date:  2022-05-02       Impact factor: 4.755

Review 5.  Targeting nitric oxide with drug therapy.

Authors:  R Preston Mason; John R Cockcroft
Journal:  J Clin Hypertens (Greenwich)       Date:  2006-12       Impact factor: 3.738

6.  A nitric oxide-releasing heparin conjugate for delivery of a combined antiplatelet/anticoagulant agent.

Authors:  Dakota J Suchyta; Hitesh Handa; Mark E Meyerhoff
Journal:  Mol Pharm       Date:  2014-01-24       Impact factor: 4.939

7.  Inhibitory effects of total saponin from Korean red ginseng via vasodilator-stimulated phosphoprotein-Ser(157) phosphorylation on thrombin-induced platelet aggregation.

Authors:  Dong-Ha Lee; Hyun-Jeong Cho; Hyun-Hong Kim; Man Hee Rhee; Jin-Hyeob Ryu; Hwa-Jin Park
Journal:  J Ginseng Res       Date:  2013-04       Impact factor: 6.060

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.